Symphogen
Ivan Horak has extensive experience in the pharmaceutical and biotech industry. Ivan currently serves as the President of Research and Development at Tessa Therapeutics Ltd. Prior to this role, they worked as the Chief Scientific and Medical Officer at Symphogen. Ivan also held the position of CSO and CMO at The Global Leaders. Ivan Horak was the Chief Scientific Officer and President of Research and Development at Eznon from 2010 to 2011. Ivan served as the CSO and president of R&D at Enzon Pharmaceuticals from 2005 to 2011. Ivan also worked as the CSO at Immunomedics from 2002 to 2005. Ivan Horak started their career at Pharmacia as the VP of Clinical Oncology from 1999 to 2002.
Ivan Horak obtained a medical degree specializing in medicine from Kommenius Medical School, where they studied from 1969 to 1975.
This person is not in any offices
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.